Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Sensitive detection of glucagon aggregation using amyloid fibril-specific antibodies.

Stimple SD, Kalyoncu S, Desai AA, Mogensen JE, Spang LT, Asgreen DJ, Staby A, Tessier PM.

Biotechnol Bioeng. 2019 Aug;116(8):1868-1877. doi: 10.1002/bit.26994. Epub 2019 May 8.

PMID:
30982957
2.

Nature-inspired design and evolution of anti-amyloid antibodies.

Julian MC, Rabia LA, Desai AA, Arsiwala A, Gerson JE, Paulson HL, Kane RS, Tessier PM.

J Biol Chem. 2019 May 24;294(21):8438-8451. doi: 10.1074/jbc.RA118.004731. Epub 2019 Mar 27.

PMID:
30918024
3.

Deamidation Can Compromise Antibody Colloidal Stability and Enhance Aggregation in a pH-Dependent Manner.

Alam ME, Barnett GV, Slaney TR, Starr CG, Das TK, Tessier PM.

Mol Pharm. 2019 May 6;16(5):1939-1949. doi: 10.1021/acs.molpharmaceut.8b01311. Epub 2019 Apr 16.

PMID:
30916563
4.

Selecting and engineering monoclonal antibodies with drug-like specificity.

Starr CG, Tessier PM.

Curr Opin Biotechnol. 2019 Feb 26;60:119-127. doi: 10.1016/j.copbio.2019.01.008. [Epub ahead of print] Review.

PMID:
30822699
5.

Net charge of antibody complementarity-determining regions is a key predictor of specificity.

Rabia LA, Zhang Y, Ludwig SD, Julian MC, Tessier PM.

Protein Eng Des Sel. 2018 Nov 1;31(11):409-418. doi: 10.1093/protein/gzz002.

PMID:
30770934
6.

Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility.

Rabia LA, Desai AA, Jhajj HS, Tessier PM.

Biochem Eng J. 2018 Sep 15;137:365-374. doi: 10.1016/j.bej.2018.06.003. Epub 2018 Jun 5.

PMID:
30666176
7.

Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.

Alam ME, Geng SB, Bender C, Ludwig SD, Linden L, Hoet R, Tessier PM.

Mol Pharm. 2018 Jan 2;15(1):150-163. doi: 10.1021/acs.molpharmaceut.7b00779. Epub 2017 Dec 6.

PMID:
29154550
8.

Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis.

Tiller KE, Chowdhury R, Li T, Ludwig SD, Sen S, Maranas CD, Tessier PM.

Front Immunol. 2017 Sep 4;8:986. doi: 10.3389/fimmu.2017.00986. eCollection 2017.

9.

Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.

Tiller KE, Li L, Kumar S, Julian MC, Garde S, Tessier PM.

J Biol Chem. 2017 Oct 6;292(40):16638-16652. doi: 10.1074/jbc.M117.783837. Epub 2017 Aug 4.

10.
11.

Facile Preparation of Stable Antibody-Gold Conjugates and Application to Affinity-Capture Self-Interaction Nanoparticle Spectroscopy.

Geng SB, Wu J, Alam ME, Schultz JS, Dickinson CD, Seminer CR, Tessier PM.

Bioconjug Chem. 2016 Oct 19;27(10):2287-2300. Epub 2016 Sep 16.

PMID:
27494306
12.

Engineered Autonomous Human Variable Domains.

Nilvebrant J, Tessier PM, Sidhu SS.

Curr Pharm Des. 2016;22(43):6527-6537. doi: 10.2174/1381612822666160921143011. Review.

13.

Measurements of Monoclonal Antibody Self-Association Are Correlated with Complex Biophysical Properties.

Geng SB, Wittekind M, Vigil A, Tessier PM.

Mol Pharm. 2016 May 2;13(5):1636-45. doi: 10.1021/acs.molpharmaceut.6b00071. Epub 2016 Apr 19.

PMID:
27045771
14.

Intrahippocampal administration of a domain antibody that binds aggregated amyloid-β reverses cognitive deficits produced by diet-induced obesity.

Osborne DM, Fitzgerald DP, O'Leary KE, Anderson BM, Lee CC, Tessier PM, McNay EC.

Biochim Biophys Acta. 2016 Jun;1860(6):1291-8. doi: 10.1016/j.bbagen.2016.03.005. Epub 2016 Mar 10.

15.

Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide.

Lee CC, Julian MC, Tiller KE, Meng F, DuConge SE, Akter R, Raleigh DP, Tessier PM.

J Biol Chem. 2016 Feb 5;291(6):2858-73. doi: 10.1074/jbc.M115.682336. Epub 2015 Nov 24.

16.

Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies.

Julian MC, Lee CC, Tiller KE, Rabia LA, Day EK, Schick AJ 3rd, Tessier PM.

Protein Eng Des Sel. 2015 Oct;28(10):339-50. doi: 10.1093/protein/gzv050. Epub 2015 Sep 19.

17.

Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy.

Wu J, Schultz JS, Weldon CL, Sule SV, Chai Q, Geng SB, Dickinson CD, Tessier PM.

Protein Eng Des Sel. 2015 Oct;28(10):403-14. doi: 10.1093/protein/gzv045. Epub 2015 Sep 12.

PMID:
26363633
18.

Advances in Antibody Design.

Tiller KE, Tessier PM.

Annu Rev Biomed Eng. 2015;17:191-216. doi: 10.1146/annurev-bioeng-071114-040733. Epub 2015 Aug 14. Review.

19.

Comparison of Human and Bovine Insulin Amyloidogenesis under Uniform Shear.

McBride SA, Tilger CF, Sanford SP, Tessier PM, Hirsa AH.

J Phys Chem B. 2015 Aug 20;119(33):10426-33. doi: 10.1021/acs.jpcb.5b04488. Epub 2015 Aug 11.

PMID:
26225416
20.

An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies.

Estep P, Caffry I, Yu Y, Sun T, Cao Y, Lynaugh H, Jain T, Vásquez M, Tessier PM, Xu Y.

MAbs. 2015;7(3):553-61. doi: 10.1080/19420862.2015.1016694.

21.

High-throughput assay for measuring monoclonal antibody self-association and aggregation in serum.

Li X, Geng SB, Chiu ML, Saro D, Tessier PM.

Bioconjug Chem. 2015 Mar 18;26(3):520-8. doi: 10.1021/acs.bioconjchem.5b00010. Epub 2015 Mar 6.

PMID:
25714504
22.

Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions.

Geng SB, Cheung JK, Narasimhan C, Shameem M, Tessier PM.

J Pharm Sci. 2014 Nov;103(11):3356-3363. doi: 10.1002/jps.24130. Epub 2014 Sep 10. Review.

23.

Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy.

Jayaraman J, Wu J, Brunelle MC, Cruz AM, Goldberg DS, Lobo B, Shah A, Tessier PM.

Biotechnol Bioeng. 2014 Aug;111(8):1513-20. doi: 10.1002/bit.25221.

PMID:
25097914
24.

High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.

Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, Vásquez M, Tessier PM, Xu Y.

MAbs. 2014 Mar-Apr;6(2):483-92. doi: 10.4161/mabs.27431. Epub 2013 Dec 6.

25.

Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process.

Tessier PM, Wu J, Dickinson CD.

Expert Opin Drug Deliv. 2014 Apr;11(4):461-5. doi: 10.1517/17425247.2014.876989. Epub 2014 Jan 21.

PMID:
24444112
26.

Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold.

Perchiacca JM, Lee CC, Tessier PM.

Protein Eng Des Sel. 2014 Feb;27(2):29-39. doi: 10.1093/protein/gzt058. Epub 2014 Jan 6.

PMID:
24398633
27.

Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro.

Li X, Zhang X, Ladiwala AR, Du D, Yadav JK, Tessier PM, Wright PE, Kelly JW, Buxbaum JN.

J Neurosci. 2013 Dec 11;33(50):19423-33. doi: 10.1523/JNEUROSCI.2561-13.2013.

28.

Modulation of curli assembly and pellicle biofilm formation by chemical and protein chaperones.

Andersson EK, Bengtsson C, Evans ML, Chorell E, Sellstedt M, Lindgren AE, Hufnagel DA, Bhattacharya M, Tessier PM, Wittung-Stafshede P, Almqvist F, Chapman MR.

Chem Biol. 2013 Oct 24;20(10):1245-54. doi: 10.1016/j.chembiol.2013.07.017. Epub 2013 Sep 12.

29.

Toward aggregation-resistant antibodies by design.

Lee CC, Perchiacca JM, Tessier PM.

Trends Biotechnol. 2013 Nov;31(11):612-20. doi: 10.1016/j.tibtech.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23932102
30.

Lifting the veil on amyloid drug design.

Tiller KE, Tessier PM.

Elife. 2013 Jul 16;2:e01089. doi: 10.7554/eLife.01089.

31.

Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates.

Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM.

Mol Pharm. 2013 Apr 1;10(4):1322-31. doi: 10.1021/mp300524x. Epub 2013 Mar 8.

PMID:
23383873
32.

Rational design of potent domain antibody inhibitors of amyloid fibril assembly.

Ladiwala AR, Bhattacharya M, Perchiacca JM, Cao P, Raleigh DP, Abedini A, Schmidt AM, Varkey J, Langen R, Tessier PM.

Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):19965-70. doi: 10.1073/pnas.1208797109. Epub 2012 Nov 15. Erratum in: Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1560.

33.

Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.

Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM.

Protein Eng Des Sel. 2012 Oct;25(10):591-601. Epub 2012 Jul 27.

PMID:
22843678
34.

Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity.

Ladiwala AR, Litt J, Kane RS, Aucoin DS, Smith SO, Ranjan S, Davis J, Van Nostrand WE, Tessier PM.

J Biol Chem. 2012 Jul 13;287(29):24765-73. doi: 10.1074/jbc.M111.329763. Epub 2012 Apr 30.

35.

Engineering aggregation-resistant antibodies.

Perchiacca JM, Tessier PM.

Annu Rev Chem Biomol Eng. 2012;3:263-86. doi: 10.1146/annurev-chembioeng-062011-081052. Epub 2012 Mar 29. Review.

PMID:
22468604
36.

Polyphenolic disaccharides endow proteins with unusual resistance to aggregation.

Ladiwala AR, Perchiacca JM, Fishman ZS, Bhattacharya M, Hickey AM, Domigan BG, Dordick JS, Tessier PM.

Biotechnol Bioeng. 2012 Jul;109(7):1869-74. doi: 10.1002/bit.24460. Epub 2012 Mar 2.

PMID:
22331747
37.

Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength.

Sule SV, Cheung JK, Antochshuk V, Bhalla AS, Narasimhan C, Blaisdell S, Shameem M, Tessier PM.

Mol Pharm. 2012 Apr 2;9(4):744-51. doi: 10.1021/mp200448j. Epub 2012 Feb 17.

PMID:
22221144
38.

Structure-based design of conformation- and sequence-specific antibodies against amyloid β.

Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM.

Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):84-9. doi: 10.1073/pnas.1111232108. Epub 2011 Dec 14.

39.

Site-specific structural analysis of a yeast prion strain with species-specific seeding activity.

Marcelino-Cruz AM, Bhattacharya M, Anselmo AC, Tessier PM.

Prion. 2011 Jul-Sep;5(3):208-14. doi: 10.4161/pri.5.3.16694. Epub 2011 Jul 1.

40.

Removal versus fragmentation of amyloid-forming precursors via membrane filtration.

Posada D, Tessier PM, Hirsa AH.

Biotechnol Bioeng. 2012 Mar;109(3):840-5. doi: 10.1002/bit.24341. Epub 2011 Nov 6.

PMID:
22012557
41.

High-throughput analysis of concentration-dependent antibody self-association.

Sule SV, Sukumar M, Weiss WF 4th, Marcelino-Cruz AM, Sample T, Tessier PM.

Biophys J. 2011 Oct 5;101(7):1749-57. doi: 10.1016/j.bpj.2011.08.036.

42.

Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions.

Perchiacca JM, Bhattacharya M, Tessier PM.

Proteins. 2011 Sep;79(9):2637-47. doi: 10.1002/prot.23085. Epub 2011 Jul 5.

PMID:
21732420
43.

Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β.

Ladiwala AR, Mora-Pale M, Lin JC, Bale SS, Fishman ZS, Dordick JS, Tessier PM.

Chembiochem. 2011 Jul 25;12(11):1749-58. doi: 10.1002/cbic.201100123. Epub 2011 Jun 10.

44.

Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways.

Ladiwala AR, Dordick JS, Tessier PM.

J Biol Chem. 2011 Feb 4;286(5):3209-18. doi: 10.1074/jbc.M110.173856. Epub 2010 Nov 23.

45.

Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers.

Ladiwala AR, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, Dordick JS, Tessier PM.

J Biol Chem. 2010 Jul 30;285(31):24228-37. doi: 10.1074/jbc.M110.133108. Epub 2010 May 28.

46.

Unraveling infectious structures, strain variants and species barriers for the yeast prion [PSI+].

Tessier PM, Lindquist S.

Nat Struct Mol Biol. 2009 Jun;16(6):598-605. doi: 10.1038/nsmb.1617.

47.

Biospecific protein immobilization for rapid analysis of weak protein interactions using self-interaction nanoparticle spectroscopy.

Bengali AN, Tessier PM.

Biotechnol Bioeng. 2009 Oct 1;104(2):240-50. doi: 10.1002/bit.22392.

PMID:
19489026
48.

Self-interaction nanoparticle spectroscopy: a nanoparticle-based protein interaction assay.

Tessier PM, Jinkoji J, Cheng YC, Prentice JL, Lenhoff AM.

J Am Chem Soc. 2008 Mar 12;130(10):3106-12. doi: 10.1021/ja077624q. Epub 2008 Feb 14.

PMID:
18271584
49.

Prion recognition elements govern nucleation, strain specificity and species barriers.

Tessier PM, Lindquist S.

Nature. 2007 May 31;447(7144):556-61. Epub 2007 May 9.

50.

Correlation of diafiltration sieving behavior of lysozyme-BSA mixtures with osmotic second virial cross-coefficients.

Tessier PM, Verruto VJ, Sandler SI, Lenhoff AM.

Biotechnol Bioeng. 2004 Aug 5;87(3):303-10.

PMID:
15281105

Supplemental Content

Loading ...
Support Center